At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Exemestane +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Exemestane, Laboratory Biomarker Analysis, and 2 other interventions for Atypical Hyperplasia and 4 related conditions. Completed, enrolled 40 participants across 3 sites.
Detailed Summary
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionDec 2023
Study CompletionAug 2025
TodayJul 2026
First PostedOct 3, 2017
Enrollment StartNov 15, 2017
Primary CompletionDec 13, 2023
Study CompletionAug 14, 2025
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 8.7 years ago
Interventions
Exemestanedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Pharmacokinetic Studyother
Correlative studies
Questionnaire Administrationother
Ancillary studies